Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Montelukast. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 known ✓ | Q9Y271 | 15/20 | 1.00 |
| ▸ | CYSLTR2 | Q9NS75 | 14/20 | 1.00 |
| ▸ | CYP2C8 | P10632 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | RECQL | P46063 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 1.00 |
| ▸ | ESR1 | P03372 | 1/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 1/20 | 1.00 |
| ▸ | FYN | P06241 | 1/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 1/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | ADRB3 | P13945 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Montelukast SCHEMBL29369663 | 1.00 | CYSLTR1 (1.00) | CYSLTR1CYSLTR2CYP2C8MEN1RECQL | |
| Montelukast SCHEMBL31060351 | 1.00 | CYSLTR1 (1.00) | CYSLTR1CYSLTR2CYP2C8MEN1RECQL | |
| Montelukast SCHEMBL15656168 | 1.00 | CYSLTR1 (1.00) | CYSLTR1CYSLTR2CYP2C8MEN1RECQL | |
| Montelukast SCHEMBL1149660 | 1.00 | CYSLTR1 (1.00) | CYSLTR1CYSLTR2CYP2C8MEN1RECQL | |
| Montelukast SCHEMBL4486 | 1.00 | CYSLTR1 (1.00) | CYSLTR1CYSLTR2CYP2C8MEN1RECQL | |
| Montelukast SCHEMBL130083 | 1.00 | CYSLTR1 (1.00) | CYSLTR1CYSLTR2CYP2C8MEN1RECQL | |
| Montelukast SCHEMBL12702747 | 1.00 | CYSLTR1 (1.00) | CYSLTR1CYSLTR2CYP2C8MEN1RECQL | |
| Montelukast SCHEMBL22207045 | 1.00 | CYSLTR1 (1.00) | CYSLTR1CYSLTR2CYP2C8MEN1RECQL | |
| Montelukast SCHEMBL21635556 | 1.00 | CYSLTR1 (1.00) | CYSLTR1CYSLTR2CYP2C8MEN1RECQL | |
| Montelukast SCHEMBL29674830 | 1.00 | CYSLTR1 (1.00) | CYSLTR1CYSLTR2CYP2C8MEN1RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 30158 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6436924-B1 | — | — | None | — | — | US | claimed |
| EP-4747263-A1 | LIPID NANOPARTICLES AND USES THEREOF | University of Connecticut (US) | 2026-05-27 | — | — | EP | claimed |
| US-20260138973-A1 | SUBSTITUTED PYRIDINES FOR USE IN TREATING OR PREVENTING INFLAMMATORY DISEASES OR DISEASES ASSOCIATED WITH AN UNDESIRABLE IMMUNE RESPONSE | SITRYX THERAPEUTICS LTD (GB) | 2026-05-21 | — | — | US | claimed |
| US-20260137680-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LTD (GB) | 2026-05-21 | — | — | US | claimed |
| CN-112236440-B | New pharmaceutical use | 艾缇亚(上海)制药有限公司 | 2026-05-15 | — | — | CN | claimed |
| US-20260124196-A1 | LEVOCETIRIZINE AND MONTELUKAST IN THE TREATMENT OF SEPSIS AND SYMPTOMS THEREOF | IRR INC (US) | 2026-05-07 | — | — | US | claimed |
| US-12616803-B2 | Apparatus for dispensing inhalant medicament | METOPI PHARMACEUTICALS, INC. (US) | 2026-05-05 | — | — | US | claimed |
| EP-4731305-A1 | NEW MULTI-FUNCTIONAL OLIGOPEPTIDES | EnliTISA (Shanghai) Pharmaceutical Co., Ltd. (CN) | 2026-04-29 | — | — | EP | claimed |
| US-20260097039-A1 | METHODS FOR TREATING A FATTY LIVER DISEASE | MADRIGAL PHARMACEUTICALS INC (US) | 2026-04-09 | — | — | US | claimed |
| US-20260097002-A1 | METHOD OF TREATMENT AND DEVICE FOR THE IMPROVED BIOAVAILABILITY OF LEUKOTRIENE RECEPTOR ANTAGONISTS | INTELGENX CORP (CA) | 2026-04-09 | — | — | US | claimed |
| WO-1999052555-A1 | METHODS AND COMPOSITIONS USING NORASTEMIZOLE IN COMBINATION WITH LEUKOTRIENE INHIBITORS | SEPRACOR INC. (US) | 1999-10-21 | — | — | WO | claimed |
| WO-1999052554-A1 | METHODS AND COMPOSITIONS USING TERFENADINE METABOLITES IN COMBINATION WITH LEUKOTRIENE INHIBITORS | SEPRACOR INC. (US) | 1999-10-21 | — | — | WO | claimed |
| WO-1999044592-A1 | ANTI-ASTHMA THERAPY | ALZA CORPORATION (US) | 1999-09-10 | — | — | WO | claimed |
| WO-1999032125-A1 | COMPOSITION FOR TREATING RESPIRATORY AND SKIN DISEASES, COMPRISING AT LEAST ONE LEUKOTRIENE ANTAGONIST AND AT LEAST ONE ANTIHISTAMINE | SCHERING CORPORATION (US) | 1999-07-01 | — | — | WO | claimed |
| EP-0737186-B1 | PROCESS FOR THE PREPARATION OF LEUKOTRIENE ANTAGONISTS | MERCK & CO INC (US) | 1998-08-19 | — | — | EP | claimed |
| WO-1998022114-A1 | A METHOD FOR PROMOTING TISSUE REPAIR | DUMEX-ALPHARMA A/S (DK) | 1998-05-28 | — | — | WO | claimed |
| EP-0480717-B1 | Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists | MERCK FROSST CANADA INC (CA) | 1998-04-15 | — | — | EP | claimed |
| EP-0737186-A1 | PROCESS FOR THE PREPARATION OF LEUKOTRIENE ANTAGONISTS | MERCK & CO. INC. (US) | 1996-10-16 | — | — | EP | claimed |
| US-5565473-A | USEFUL AS ANTI-ASTHMATIC, ANTI-ALLERGIC, ANTI-INFLAMMATORY AND CYTOPROTECTIVE AGENTS; MONTELUKAST AND ITS SODIUM SALT | MERCK FROSST CANADA, INC. (CA) | 1996-10-15 | — | — | US | claimed |
| WO-1995018107-A1 | PROCESS FOR THE PREPARATION OF LEUKOTRIENE ANTAGONISTS | MERCK & CO., INC. (US) | 1995-07-06 | — | — | WO | claimed |